Dr. Deepu Madduri is an Assistant Professor of Medicine (Hematology and Medical Oncology) and Assistant Director, Cellular Therapy Service, with the Center of Excellence for Multiple Myeloma at The Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai. She received her MD from the University of Oklahoma and completed her residency in internal medicine at St. Mary Medical Center. She then went on to complete fellowships in hematology oncology at Harbor-UCLA Medical and in bone marrow transplant at Stanford University Hospital.
Dr. Madduri specializes in the study and treatment of relapsed and refractory multiple myeloma. Her research has included first-in-human/Phase I clinical trial studies ranging from immunotherapy with checkpoint inhibitors and immune effector cells such as CAR T-cell therapy, NK-cell therapy, and bispecific antibodies. Dr. Madduri has played an integral role in initiating CAR T-cell studies for myeloma.
She has played an integral role in initiating CAR T-cell studies for myeloma. She is also a member of the Clinical Research Services team for cellular therapies at Mount Sinai and a member of the Bone Marrow Transplant Clinical Trials Network protocol committee.
Dr. Madduri serves as an oncology consultant at Foundation Medicine, Inc., a cancer genomic company, and leads their Smart Trials Precision enrollment program. She is board-certified in hematology and medical oncology and has been published in several peer-reviewed publications.
Not All CAR T-Cells Are the Same: CARTITUDE Study
Myeloma expert Dr. Deepu Madduri discusses patient response data from the CARTITUDE-1 Study, which uses an investigational CAR T-cell therapy JNJ-4528 that targets BCMA.